Bronchial asthma is a common, chronic disease that seriously endangers people’s health and workforce. Nevertheless, not everyone is familiar with this disease. A typical asthma attack presents as a sudden onset of expiratory dyspnea, and croup can be heard by the patient or those around them. Atypical ones may manifest as episodes of chest tightness, or an intractable cough. The clinical characteristics are: sudden onset of symptoms with some triggers, such as inhalation of certain allergens or irritating odors; certain seasonal pattern of asthma attacks in some patients; easy to attack or intensify at night or early in the morning; symptoms can be relieved by themselves or after treatment; easy to recur after symptoms are relieved. For a long time, it has been believed that bronchial asthma is caused by bronchial smooth muscle spasm, and thus the treatment emphasizes the application of various bronchodilators. Recent studies have confirmed that bronchial asthma is a chronic airway inflammation involving a variety of inflammatory cells, especially mast cells, eosinophils, and t-lymphocytes, with not only bronchial smooth muscle spasm, but also increased capillary wall permeability, increased exudation, mucosal edema mucous gland hyperplasia, and mucus retention. Pneumonia are caused by a variety of bacteria involved in the inflammatory cells are mainly neutrophils, the application of sensitive antibiotic treatment can receive better results. In contrast, the airway inflammation in asthma patients is mostly caused by inhalation of allergens, etc. The inflammatory cells are mainly mast cells, eosinophils, and t-lymphocytes. The application of antibiotic treatment is ineffective, and the application of adrenal glucocorticoids is required.